<DOC>
	<DOCNO>NCT00795886</DOCNO>
	<brief_summary>Objectives : Primary objective : Evaluate toxicity rapamycin use post-bone marrow transplant graft vs. host disease prophylaxis child acute lymphoblastic leukemia ( ALL ) . Investigator initiate ; four participating institution ; Phase II pilot study</brief_summary>
	<brief_title>Rapamycin Immunosuppression B Cell Modulation Post Stem Cell Transplant Acute Lymphoblastic Leukemia ( ALL )</brief_title>
	<detailed_description>Objectives : Primary objective : Evaluate toxicity rapamycin use post-bone marrow transplant graft vs. host disease prophylaxis child acute lymphoblastic leukemia ( ALL ) . Rapamycin Rapamycin ( RAPA , RapamuneR ) ( sirolimus ) immunosuppressive agent approve FDA 1999 . It macrocyclic lactone structurally similar Tacrolimus ( FK506 ) bind intracellular protein FK506 , FKBP1,2,3 , entirely different mechanism action different principal target protein . The target RAPA : FKBP complex mammalian target rapamycin ( mTOR ) . Unlike calcineurin inhibitor cyclosporine ( CSA ) - FK506 , RAPA exert effect inhibit growth factor-driven transduction signal T-cell response alloantigen , thus prevent proliferation among T B lymphocytes3,4 . This action later stage T cell mediate response CSA FK506 . Important cyclin-dependent signaling kinase block , result cell cycle arrest G1 S phase . RAPA prevents factor dependent growth activate T cell , prevent autocrine production release growth factor activate T cell . Rapamycin study clinical trial solid organ allograft , show prolong allograft survival inhibit host CD4+ CD8+ T cell expansion5 , 6 . RAPA synergistic immunosuppressive property use CSA FK506 , use allows low dos nephrotoxic calcineurin inhibitor accomplish decrease rejection . The use full dose calcineurin inhibitor RAPA result nephrotoxicity , agent safely use reduce dose RAPA . Our goal Rapamycin achieve two necessary end one medication : leukemic precursor effect ( see ) , prevention graft vs. host disease ( GVHD ) . With CSA OR FK506 , acute GVHD develop approximately 40 % pediatric match related donor recipient , majority mild easily controllable addition methylprednisolone prednisone . At Children 's hospital Philadelphia ( CHOP ) , `` short course '' methotrexate addition CSA OR FK506 give patient &gt; 14 year , old donor . Chronic GVHD occur approximately 20 % pediatric match related donor recipient , 75 % limited skin . Therefore , use RAPA group may accomplish adequate immunosuppression prevent GVHD , well provide anti- B anti-T cell malignancy effect . RAPA may also prove less toxic calcineurin inhibitor well , nephrotoxicity neurotoxicity remain serious side effect . Allogeneic bone marrow transplantation child ALL Children high-risk feature , ( 4 ; 11 ) ( 9 ; 22 ) , relapse chemotherapy rarely cure chemotherapy alone . These patient , well beyond second remission , generally refer allogeneic stem cell transplantation . Approximately 25-30 % patient match sibling donor . Matched sibling , match unrelated , cord blood donor bone marrow transplant result approximately 40-60 % patient survive disease free , relapse remain large obstacle cure . Rapamycin , apoptotic effect upon B cell precursor malignancy , may prove effective decreasing incidence relapse patient , particularly use state minimal residual disease post transplant . We expect treat approximately 10 patient ALL yearly match relate donor BMT four center involve study . Rapamycin study conjunction calcineurin inhibitor ( CSA FK506 ) At Dana Farber Cancer Institute ( DFCI ) , 50 patient related , human leukocyte antigen ( HLA ) match peripheral stem cell transplant study use combination FK506 repaying . The hypothesis test omission methotrexate would increase rate GVHD , would reduce toxicity . The rate grade II-IV acute GVHD 16 % , III-IV 5 % , extremely favorable adult . Transplant related mortality 100 day 5 % . This study do follow earlier study low dose methotrexate high risk unrelated donor transplant patient . This study show rapamycin provide excellent GVHD prevention high-risk cohort . We substitute FK506 cyclosporine per Boston experience . This consider standard practice within division increase patient compliance comfort . This increase risk patient , oral FK506 well tolerate RAPA FK506 appear synergistic may result good GVHD prophylaxis . Study Procedures : Conditioning : 1 . Thiotepa 5 mg/kg day -7 , -6 . Given IV 4 hour . Cyclophosphamide 60 mg/kg day -5 , -4 . Given 1 hour IV routine supportive care . 2 . Total body irradiation ( TBI ) 200 cGy/fraction x 6 fraction give 3 days* . Testicular boost 400 cGy may give male . Patients prior CNS disease prior central nervous system ( CNS ) irradiation : 600 cGy prior start condition . *TBI may give Thiotepa cyclophosphamide . If give Stem cell give 48 hour end cyclosphosphamide . Graft v . Host Disease Prophylaxis : 1 . Tacrolimus IV continuous infusion .03mg/kg per day begin day -3 . Target serum level 5-10 patient switch oral form tolerate PO 's ( `` Per Os '' `` By mouth '' . 2 . Methotrexate 5mg/m2 give IV day 1 , 3 , 6 patient day 11 patient receive unrelated donor marrow . 3 . Rapamycin day 0 dosing follow : 2.5 mg/m2/d ( 4mg/d max ) PO daily . Absent GVHD Immune Suppression Weaning : 1 . Tacrolimus : Matched sibling donor allograft taper day +42 6-8wks . Mismatched unrelated allograft cord blood taper day +100 day +180 . 2 . Sirolimus : At day + 180 wean 4 week .</detailed_description>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Precursor Cell Lymphoblastic Leukemia-Lymphoma</mesh_term>
	<mesh_term>Leukemia , Lymphoid</mesh_term>
	<mesh_term>Sirolimus</mesh_term>
	<mesh_term>Everolimus</mesh_term>
	<criteria>1 . Pediatric patient ' age ( 0 21 year ) lymphoid malignancy consider allogeneic bone marrow transplant HLAidentical sibling donor , single antigen mismatch related unrelated donor marrow /peripheral blood stem cell ( PBSC ) cord blood available marrow donation . First remission : remission achieve day28 high risk cytogenetic feature , include ( 9 ; 22 ) ( 4 ; 11 ) Second third remission 2 . Signed informed consent . 1 . Organ criterion : 1 . Cardiac : ECHO shorten fraction &lt; 27 % 2 . Renal : Creatinine clearance &lt; 60 ml/min/1.73 m2 3 . Hepatic : Bilirubin &gt; 1.5 mg/dl , transaminases &lt; 3x normal 4 . Infection : active viral , fungal bacterial infection include HIV .</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>21 Years</maximum_age>
	<verification_date>July 2013</verification_date>
	<keyword>ALL</keyword>
	<keyword>Cancer</keyword>
	<keyword>Stem Cell Transplant</keyword>
</DOC>